UK-based firm LivaNova has started the RESTORE-LIFE study to investigate the use of its Vagus Nerve Stimulation (VNS) Therapy System for treatment-resistant depression (TRD).

The VNS system comprises a programmable electronic pulse generator connected to a bipolar electrical lead that sends mild pulses to trigger the vagus nerve at regular intervals throughout the day.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The global prospective, multi-centre, observational, post-market study will evaluate the short, mid and long-term effectiveness and efficiency of VNS therapy as an adjunctive treatment in real-world patients.

LivaNova plans to enrol at least 500 participants, who could not experience an adequate response to standard psychiatric management, at around 80 sites across various countries.

The first patient for the study has been already recruited at the Universitätsklinikum Jena in Germany.

“This post-market study will allow us to have a better understanding of this treatment-resistant patient population.”

During the study, patients will be implanted with the therapy and undergo follow-up for a minimum of three years and a maximum of five to monitor changes in clinical symptoms due to the VNS Therapy.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The study will measure response at one year as the primary endpoint, along with secondary endpoints and factors such as quality of life, patient function and adjunctive antidepressant treatments.

LivaNova Clinical, Regulatory and Quality senior vice-president Bryan Olin said: “This post-market study will allow us to have a better understanding of this treatment-resistant patient population and the significant role VNS Therapy can play in the overall management of this disease.

“RESTORE-LIFE is unique in the fact that clinical response, patient functioning and resource utilisation will be followed up globally for five years, amassing high-quality, real-world clinical data on VNS Therapy as an adjunctive treatment for difficult-to-treat depression.”